Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2793-2799

  Mir, Olivier ^a   Coriat, Romain ^a   Boudou Rouquette, Pascaline ^a   Ropert, Stanislas ^a   Durand, Jean Philippe ^a   Cessot, Anatole ^a   Mallet, Vincent ^a   Sogni, Philippe ^a   Chaussade, Stanislas ^a   Pol, Stanislas ^a   Goldwasser, François ^a  

^a Institut Cochin   (France)

Author keywords

Angiogenesis inhibitors; Cirrhosis; Gemcitabine; Hepatocellular carcinoma; Oxaliplatin; Sarcopenia; Sorafenib

Indexed keywords

GEMCITABINE; OXALIPLATIN; SORAFENIB;

ADULT; AGED; ANEMIA; ARTICLE; BODY COMPOSITION; CANCER COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; MUSCLE ATROPHY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; ORGANOPLATINUM COMPOUNDS; PHENYLUREA COMPOUNDS;

EID: 84867968828     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0208-x     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907-17. doi: 10.1016/S0140-6736(03)14964-1.
3. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5(10):835-44. doi: 10.1038/nrd2130.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90. doi: 10.1056/NEJMoa0708857.
5. Jelic S, Sotiropoulos GC. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v59-64. doi: 10.1093/annonc/mdq166.
6. Alexandre J, Tigaud JM, Gross-Goupil M, Gornet JM, Romain D, Azoulay D, et al. Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients. Am J Clin Oncol. 2002;25(2):198-203.
7. Coriat R, Mir O, Cessot A, Brezault C, Ropert S, Durand JP, et al. Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. Invest New Drugs. 2010;. doi: 10.1007/s10637-010-9525-0.
8. Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer. 2007;109(7):1384-90. doi: 10.1002/cncr.22532.
9. Taieb J, Bonyhay L, Golli L, Ducreux M, Boleslawski E, Tigaud JM, et al. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer. 2003;98(12):2664-70. doi: 10.1002/cncr.11869.
10. Faivre S, Le Chevalier T, Monnerat C, Lokiec F, Novello S, Taieb J, et al. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol. 2002;13(9):1479-89.
11. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol. 1999;44(2):117-23.
12. Mir O, Alexandre J, Ropert S, Amsellem-Ouazana D, Flam T, Beuzeboc P, et al. Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities. Anticancer Drugs. 2005;16(9):1017-21.
13. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9(10):1053-71.
14. Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, et al. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2007;13(12):3660-6. doi: 10.1158/1078-0432.CCR-06-2385.
15. Takimoto CH, Graham MA, Lockwood G, Ng CM, Goetz A, Greenslade D, et al. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res. 2007;13(16):4832-9. doi: 10.1158/1078-0432.CCR-07-0475.
16. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489-95. doi: 10.1016/S1470-2045(10)70218-7.
17. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629-35. doi: 10.1016/S1470-2045(08)70153-0.
18. Durand JP, Madelaine I, Scotte F. Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting. Bull Cancer. 2009;96(10):951-60. doi: 10.1684/bdc.2009.0924.
19. Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2011;23(1):200-5. doi: 10.1093/annonc/mdr045.
20. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol. 1998;85(1):115-22.
21. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33(5):997-1006. doi: 10.1139/H08-075.
22. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15(8):2920-6. doi: 10.1158/1078-0432.CCR-08- 2242.
23. Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst. 1990;82(12):1046-50.
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-16.
25. Cosqueric G, Sebag A, Ducolombier C, Thomas C, Piette F, Weill-Engerer S. Sarcopenia is predictive of nosocomial infection in care of the elderly. Br J Nutr. 2006;96(5):895-901.
26. Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ, Reiman T, et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol. 2010;67(1):93-101. doi: 10.1007/s00280-010-1288-y.
27. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010;21(8):1594-8. doi: 10.1093/annonc/mdp605.
28. Meza-Junco J, Montano-Loza A, Prado CMM, Lieffers JR, Baracos VE, Bain V, Spratlin JL, Sawyer MB. Sarcopenia in patients (pts) with hepatocelluar carcinoma (HCC). J Clin Oncol. 2011;29(suppl):e14570.
29. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol. 2010;28(6):1054-60. doi: 10.1200/JCO.2009.24.9730.